Faeth Therapeutics Inc Dossier - Source-backed chat

Faeth Therapeutics Inc

FTHNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.15

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $28.27Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $730.5M

Shares Outstanding 25.8M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Faeth Therapeutics (formerly Sensei Biotherapeutics, trading under Nasdaq: FTH) represents a highly compelling clinical-stage oncology play following its reverse merger and rebranding in June 2026. The company is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway, which is the most frequently altered oncogenic pathway in cancer. Its lead program, PIKTOR, is an all-oral combination of serabelisib (PI3K-alpha inhibitor) and sapanisertib (mTORC1/2 inhibitor) designed to achieve deeper pathway suppression and overcome feedback-driven resistance. Backed by a robust $200 million cash position from its concurrent private placement, Faeth is well-capitalized to advance its clinical pipeline. With near-term Phase 2 topline data in advanced endometrial cancer expected in H2 2026, the stock offers an asymmetric risk-reward profile supported by strong initial Phase 1b data (80% ORR in endometrial cancer).

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$50.00

Mean target$54.00

High · most bullish analyst$60.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$24.0020%

The Phase 2 endometrial cancer trial fails to replicate the high response rates of earlier studies, or reveals unexpected dose-limiting toxicities that compromise the safety profile of the all-oral combination. This leads to clinical delays, trial design modifications, or program termination, severely impacting the company's valuation and forcing a reliance on earlier-stage pipeline assets.

Base CaseCentral scenario

$54.0050%

Matches the consensus mean

The Phase 2 endometrial cancer trial meets its primary endpoints in H2 2026, demonstrating a clinically meaningful and competitive ORR and progression-free survival (PFS) with a manageable safety profile. The company successfully progresses its Phase 1b/2 breast cancer trial, maintaining its cash runway into late 2027/2028. The stock trades in line with the consensus analyst target as clinical milestones are systematically de-risked.

Bull CaseUpside scenario

$60.0030%

The Phase 2 endometrial cancer trial delivers outstanding topline results in H2 2026, confirming or exceeding the 80% ORR seen in early trials with excellent tolerability. This accelerates the clinical development timeline, potentially positioning PIKTOR for a breakthrough therapy designation and a rapid path to regulatory approval. Strong clinical execution and positive early signals from the breast cancer trial in 2027 attract major pharmaceutical partnerships, driving the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Multi-Node Mechanism: PIKTOR targets three critical nodes of the PAM pathway simultaneously (PI3K-alpha upstream, mTORC1 and mTORC2 downstream), preventing the feedback loops and resistance mechanisms that have historically limited single-node therapies.
Strong Preliminary Efficacy: Early clinical data demonstrated an impressive 80% objective response rate (ORR) when combining the PIKTOR regimen with paclitaxel in patients with advanced endometrial cancer.
Robust Balance Sheet: The company is exceptionally well-capitalized with approximately $200 million in gross proceeds from its February 2026 private placement, providing a solid cash runway through major clinical catalysts.
Highly Experienced Leadership: Led by co-founder and CEO Anand Parikh alongside a distinguished board of directors, including former FDA Commissioner Dr. Stephen M. Hahn.

Key Investment Risks

Clinical Development Risk: As a clinical-stage biotech, Faeth's valuation is heavily dependent on the success of its ongoing trials. Failure to meet endpoints in the upcoming H2 2026 endometrial cancer readout would severely impact the stock.
Toxicity and Tolerability: Combining multiple pathway inhibitors can lead to cumulative toxicities (e.g., hyperglycemia, gastrointestinal issues). Maintaining a tolerable safety profile in larger patient cohorts is critical.
Market Competition: The oncology space, particularly targeting the PI3K/AKT/mTOR pathway, is highly competitive with several established pharmaceutical companies and biotechnology firms developing rival therapies.

Thesis Invalidation Triggers

Failure of the Phase 2 endometrial cancer trial to meet its primary efficacy or safety endpoints in H2 2026.
Severe, unexpected adverse events leading to a clinical hold on the PIKTOR program by the FDA.
Significant delays in patient enrollment or trial execution that exhaust the company's cash runway prematurely.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.